{"classes":[{"categories":[{"measurements":[{"groupId":"OG001","lowerLimit":"2.30","upperLimit":"2.76","value":"2.53"},{"groupId":"OG002","lowerLimit":"4.11","upperLimit":"15.01","value":"9.56"},{"groupId":"OG003","lowerLimit":"3.71","upperLimit":"3.71","value":"3.71"},{"groupId":"OG004","lowerLimit":"2.27","upperLimit":"2.79","value":"2.53"},{"groupId":"OG005","lowerLimit":"2.30","upperLimit":"6.31","value":"3.94"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"21"}],"units":"Participants"}],"description":"Time to complete response (CR) was measured from the start of moxetumomab pasudotox treatment to the first documentation of CR and was evaluated only in participants who received any treatment of moxetumomab pasudotox and had achieved a CR. Time to complete response was summarized using Kaplan-Meier estimates (median time, 95% confidence interval \\[CI\\] for median time).","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received IV 5 mcg/kg moxetumomab pasudotox on Days 1, 3, and 5 of every 28-day cycle and continued until complete response (CR), progressive disease (PD), initiation of alternative anticancer therapy, unacceptable toxicity, development of neutralizing antibodies, or another reason to discontinue therapy.","id":"OG000","title":"5 mcg/kg"},{"description":"Participants received IV 10 mcg/kg moxetumomab pasudotox on Days 1, 3, and 5 of every 28-day cycle and continued cycles of therapy until CR, PD, initiation of alternative anticancer therapy, unacceptable toxicity, development of neutralizing antibodies, or another reason to discontinue therapy.","id":"OG001","title":"10 mcg/kg"},{"description":"Participants received IV 20 mcg/kg moxetumomab pasudotox on Days 1, 3, and 5 of every 28-day cycle and continued cycles of therapy until CR, PD, initiation of alternative anticancer therapy, unacceptable toxicity, development of neutralizing antibodies, or another reason to discontinue therapy.","id":"OG002","title":"20 mcg/kg"},{"description":"Participants received IV 30 mcg/kg moxetumomab pasudotox on Days 1, 3, and 5 of every 28-day cycle and continued cycles of therapy until CR, PD, initiation of alternative anticancer therapy, unacceptable toxicity, development of neutralizing antibodies, or another reason to discontinue therapy.","id":"OG003","title":"30 mcg/kg"},{"description":"Participants received IV 40 mcg/kg moxetumomab pasudotox on Days 1, 3, and 5 of every 28-day cycle and continued cycles of therapy until CR, PD, initiation of alternative anticancer therapy, unacceptable toxicity, development of neutralizing antibodies, or another reason to discontinue therapy.","id":"OG004","title":"40 mcg/kg"},{"description":"Participants received IV 50 mcg/kg moxetumomab pasudotox on Days 1, 3, and 5 of every 28-day cycle and continued cycles of therapy until CR, PD, initiation of alternative anticancer therapy, unacceptable toxicity, development of neutralizing antibodies, or another reason to discontinue therapy.","id":"OG005","title":"50 mcg/kg"}],"paramType":"MEDIAN","populationDescription":"Safety population included all participants who received any treatment of moxetumomab pasudotox. The \"Overall Number of Participants Analyzed\" denotes the number of participants who had achieved a CR.","reportingStatus":"POSTED","timeFrame":"From Baseline (predose of Cycle 1 Day 1) through end of study (until CR, PD, initiation of alternative therapy, unacceptable toxicity, development of neutralizing antibodies, or other study discontinuation reasons) (approximately 8 years)","title":"Time to Complete Response","type":"PRIMARY","unitOfMeasure":"months"}